Apellis Pharmactdl 0001 Stock Total Debt
| 1JK Stock | EUR 28.70 0.21 0.74% |
APELLIS PHARMACTDL 0001 fundamentals help investors to digest information that contributes to APELLIS PHARMACTDL's financial success or failures. It also enables traders to predict the movement of APELLIS Stock. The fundamental analysis module provides a way to measure APELLIS PHARMACTDL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to APELLIS PHARMACTDL stock.
APELLIS |
APELLIS PHARMACTDL 0001 Company Total Debt Analysis
APELLIS PHARMACTDL's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current APELLIS PHARMACTDL Total Debt | 409.63 M |
Most of APELLIS PHARMACTDL's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, APELLIS PHARMACTDL 0001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, APELLIS PHARMACTDL 0001 has a Total Debt of 409.63 M. This is 85.11% lower than that of the Healthcare sector and 26.12% higher than that of the Biotechnology industry. The total debt for all Germany stocks is 92.3% higher than that of the company.
APELLIS Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses APELLIS PHARMACTDL's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of APELLIS PHARMACTDL could also be used in its relative valuation, which is a method of valuing APELLIS PHARMACTDL by comparing valuation metrics of similar companies.APELLIS PHARMACTDL is currently under evaluation in total debt category among its peers.
APELLIS Fundamentals
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 89.16 % | |||
| Revenue | 113.05 M | |||
| Gross Profit | (253.92 M) | |||
| EBITDA | (518.43 M) | |||
| Net Income | (460.28 M) | |||
| Cash And Equivalents | 599.01 M | |||
| Cash Per Share | 6.89 X | |||
| Total Debt | 409.63 M | |||
| Debt To Equity | 7.94 % | |||
| Current Ratio | 4.15 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (239.85 M) | |||
| Earnings Per Share | (7.48) X | |||
| Target Price | 67.81 | |||
| Number Of Employees | 767 | |||
| Beta | 1.23 | |||
| Market Capitalization | 5.78 B | |||
| Z Score | 8.4 |
About APELLIS PHARMACTDL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze APELLIS PHARMACTDL 0001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of APELLIS PHARMACTDL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of APELLIS PHARMACTDL 0001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.